投融资数据库
免费查数据
注册送3天会员
首页>投融资
Allergy Therapeutics
上市
Allergy Therapeutics plc is a UK-based specialized pharmaceutical company developing therapeutics to treat and prevent allergies. It was formed in June 1998, through a management buy-out of the Bencard allergy vaccine business of SmithKline Beecham.At the time of its formation, Allergy Therapeutics already marketed an established range of specific immunotherapy diagnostics and therapies, including its range of Pollinex allergy desensitizing vaccines, under the brand name Bencard. The vaccines, produced in the manufacturing facility in Worthing, UK were sold through Allergy Therapeutics' sales force in Germany, Spain, Italy, Poland and Canada and through licensees in other European and Asian countries. The company's R&D activities were located in the UK and Germany.By February 2006, Allergy Therapeutics had developed and launched OralVac, a sublingual vaccine comprised of a specific mix of allergens, tailored to suit individual patients. The vaccine was available in several European countries, on
基本信息
-
公司全称Allergy Therapeutics PLC
-
类型一家专注于治疗和预防过敏的欧洲专业制药公司
-
产业领域医药研发/制造、化学&生物药
-
公司人数500人以上
-
地址Dominion Way WORTHING WEST SUSSEX BN14 8SA; GB; Telephone: +441903844700; Fax: +441903844726;
-
联系电话44(0)1903844700
-
邮箱businessdevelopment@allergytherapeutics.com
-
成立时间1979-01-01
相关投融资企业
B+轮
北京安龙基因医药技术有限公司专注于生命科学领域对新药研发的突破性进展,包括基因治疗,基因编辑,DNA及RNA等其它遗传物质做为新药研发的方向,获得泰格医药等投资机构6000万资金支持。安龙生物产品在病毒、DNA基因治疗的稳定性和携带性上均表现出较强优势,基于AAV对组织的特异性侵染、AAV载体对眼科疾病的基因治疗等代表性研究成果已发表在Nature Microbiology, Plos ONE等国际期刊,在研项目包括老年黄斑变性(AMD)基因药物和针对血友病A型的基因治疗项目。
A轮
慧心医谷成立于2021年,是一家聚焦于神经系统疾病细胞治疗领域的创新生物医药企业。慧心医谷运用前沿的重编程技术和非整合系统,从人的外周血单个核细胞或成纤维细胞,直接诱导获得神经干细胞(iNSC)。并将其定向分化为多巴胺能神经前体细胞(iNSC-DAP),通过国际领先的立体定向移植临床技术,对帕金森病(PD)进行临床干预治疗
A轮
Corsera Health旨在通过心血管疾病预测和预防延长健康寿命,引领医学的未来。该公司由RNAi疗法和心血管医学领域的行业先驱共同创立,将数十年的RNAi疗法创新与心血管疾病预测、高效制造和证据生成以及颠覆性商业化方面的世界领先专业知识相结合。Corsera Health 总部位于马萨诸塞州波士顿。



浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息